



Swansea University  
Prifysgol Abertawe



## Cronfa - Swansea University Open Access Repository

---

This is an author produced version of a paper published in:  
*Journal of Diabetes Science and Technology*

Cronfa URL for this paper:  
<http://cronfa.swan.ac.uk/Record/cronfa35082>

---

### **Paper:**

Barnard, K., Kropff, J., Choudhary, P., Neupane, S., Bain, S., Kapitza, C., Forst, T., Link, M., Mdingi, C. et. al. (2017). Acceptability of Implantable Continuous Glucose Monitoring Sensor. *Journal of Diabetes Science and Technology*

---

This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior permission for personal research or study, educational or non-commercial purposes only. The copyright for any work remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium without the formal permission of the copyright holder.

Permission for multiple reproductions should be obtained from the original author.

Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the repository.

<http://www.swansea.ac.uk/iss/researchsupport/cronfa-support/>

## **Acceptability of Implantable Continuous Glucose Monitoring Sensor**

Running Title: Psych Impact of Implantable CGM

Katharine D Barnard PhD<sup>1,2</sup>, Jort Kropff MD PhD<sup>3</sup>, Pratik Choudhary MD<sup>4</sup>, Sankalpa Neupane MBBS, MRCP(UK)<sup>5</sup>, Stephen C Bain MA MD FRCP<sup>6</sup>, Christoph Kapitza MD<sup>7</sup>, Thomas Forst MD<sup>8</sup>, Manuela Link MD<sup>9</sup>, Colleen Mdingi MS<sup>10</sup> and J Hans DeVries MD PhD<sup>3</sup>

1. Faculty of Health and Social Sciences, Bournemouth University, Bournemouth, UK
2. BHR Limited, Fareham, UK
3. Department of Endocrinology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands
4. King's College London, London, U.K
5. Cambridge University Hospitals NHS Foundation Trust, Cambridge, U.K.
6. Joint Clinical Research Facility, Swansea University, Swansea, U.K.
7. Profil, Neuss, Germany
8. Profil, Mainz, Germany
9. Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany
10. Research, Senseonics Inc., Germantown, MD

**Word count: 1687**

**No of Tables: 3**

Correspondence Author:  
Professor Katharine Barnard  
BHR Limited  
42 Kilmiston Drive  
Fareham  
Hampshire PO16 8EG  
United Kingdom  
T: +44 (0)7590 532866  
E: katharinebarnard@bhrltd.com

Key words: implantable; type 1 diabetes; psychosocial; continuous glucose monitoring

### **Funding:**

This study was funded by Senseonics Inc.

**Abstract:**

**Background:** Real-time continuous glucose monitoring is associated with significant benefits for diabetes management. Implantable sensors could overcome some challenges reportedly associated with device visibility, psychosocial functioning and sensor durability.

**Methods:** A psychosocial assessment was conducted to determine acceptability and impact of an implantable continuous glucose monitoring (CGM) sensor as part of the PRECISE trial. Questionnaires were administered to participants comprising the diabetes distress scale, the CGM impact scale and bespoke device satisfaction.

**Results:** Fifty-one participants across UK (n=10) and Germany (n=41) completed the questionnaires. Of these, 90% had T1D, 50% followed an insulin pump therapy regimen, and 45% of the participants were previous CGM users. CGM Impact Scale results show 86% (n=44) of participants reported feeling better (14% neutral) about their diabetes control with 90% CGM naïve participants and 81% previous CGM users reporting increased confidence about their diabetes management. Furthermore, 73% (n=37) felt more safe (27% neutral) while sleeping and 78% (n=39) more confident (22% neutral) about avoiding serious hypoglycemia. Responses correspond with an average improvement in HbA1c from 7.51 to 7.05 ( $p<.0001$ ) over the 90 days use of the CGM. Overall, the system was rated highly on ease of use, convenience and comfort. 84% would choose to be inserted again with 93% of CGM naïve participants (86% previous CGM users) reporting minimized burden of diabetes.

**Conclusions:** Implantable CGM devices are acceptable to users and are evaluated favourably. The considerable majority of participants (93% of first time users and 77% previous CGM users) would like to continue using the system to help manage their diabetes more effectively.

## Acceptability of Implantable Continuous Glucose Monitor Sensor

### **Background:**

An important technical innovation for type 1 diabetes has been the introduction of real time systems providing information on glucose trajectories and trends for users to improve their diabetes self-management decisions. CGM has been shown to be clinically effective and to enhance psychosocial outcomes such as increased confidence in diabetes self-management [1]. Inter-individual variability is substantial however with some users not realizing such benefits [2]. In particular, benefits seem to depend on duration of use, and in some groups with low usage, there have been limited benefits [3]

Downsides to the technology have focused on poor reliability, alarm fatigue, frequent changes of sensors (typically every 6-7 days), increased burden associated with diabetes self-management and visibility of disease state with the need for additional sensors/transmitter and receiving device [4,5]. A recently introduced implantable sensor with a duration of three to six months with connectivity through smartphone technology may address issues of regular usage, longevity and to some extent visibility of disease state.

The aim of the current study was to explore the psychosocial outcomes associated with wearing an implantable CGM for six months. Key issues include impact of device on perceptions of diabetes self-management and diabetes control; usability; safety; social relationships and fear of hypoglycemia.

### **Methods:**

A psychosocial sub-study was conducted as part of the PRECISE trial, a 180-day prospective multicenter pivotal trial [6]. Participants aged 18 years or older with type 1 or type 2 diabetes were implanted with the implantable Eversense (Senseonics Inc) CGM sensor. The sensor was placed in participants' upper arm with the removable transmitter positioned on the skin over the sensor. Quantitative psychosocial assessments were administered at

ninety days to participants to explore patient reported outcomes associated with an implantable CGM sensor. The questionnaire comprised the Diabetes Distress Scale (DDS)[7], a twenty-eight item scale which assesses worries and concerns specifically related to diabetes and its management; it has been shown to be a good marker of factors important to diabetes-related Quality of Life (QoL). Responses are rated on a 6-point scale from 'not a problem' to 'a very serious problem'; the CGM Impact Scale [8] which is a sixteen item scale assessing experiences with CGM and designed to measure the impact of CGM on diabetes management and family relationships, plus on satisfaction with emotional, behavioral and cognitive effects of CGM use. Responses are rated on a 5-point scale from 'much better' to 'much worse'; and thirty-three bespoke device satisfaction questions, which were developed by a multi-disciplinary team for this study to assess acceptability of the device. Questions were both open-ended and likeart scale response (range 1-7, strongly agree to disagree) focusing on participant experience of using the CGM, its features, functionality and usability. The questionnaire bank was piloted with potential participants prior to use and minor revisions made.

Quantitative analysis was conducted using SPSS v.21 and free text responses were analyzed using content and thematic methodology. Two researchers independently reviewed all free text responses, and consensus of key themes reached.

### **Results:**

Fifty-one participants took part in the study across the UK ( $n=10$ ) and Germany ( $n=41$ ). Of these, forty-six had T1D, five had T2D. Participants were similarly split between multiple daily injections (MDI) ( $n=25$ ) and insulin pump therapy regimen ( $n=26$ ). Similarly, 55% of participants were first time users of CGM ( $n=28$ ), 45% were current or previous CGM users

Table 1 shows the frequency of which participants looked at the glucose display on their iPod, subdivided by mode of therapy and first vs. previous CGM users. Recommended daily checking frequency of blood glucose is around four times a day, however the ability to easily see the reading without having to perform a finger prick check is commonly associated with greater

frequency of checking. This was reflected in the current study where all participants reporting having viewed their CGM data more frequently than they had done so prior to enrolling in the study.

*Insert table one about here*

CGM impact scale data shows that participants report improvements in terms of confidence over their diabetes control (85%), blood glucose levels (60%) and optimism about avoiding long-term complications (78%). Furthermore, participants reported feeling safer when sleeping (72%), more confident about avoiding severe hypoglycemia (76%) and more motivated to keep up with their diabetes management (80%) (see Table 2).

Overall, the system was rated highly on ease of use, convenience and comfort with 92% indicated that they did not experience pain or discomfort when using the sensor. 84% would choose to be inserted again with 93% of CGM naïve participants (86% previous users) reporting minimized burden of diabetes. Previous CGM users reported better sensor comfort (82% vs 71%) and were more likely to use the sensor for every day management than naïve users (93% vs 77%).

*Insert table two about here*

Participants reported improvements on all domains of the diabetes distress scale, i.e. emotional burden, physician-related distress, regime-related distress and interpersonal distress (see Table 3). Furthermore, 72% ( $n=36$ ) judged the CGM to be very helpful in managing their diabetes more easily (score 8-10) on a scale of 1-10, 18% ( $n=9$ ) scored 4-7 and 8% scored 1-3 not very helpful.

*Insert table three about here*

Free text responses identified key themes in terms of what participants particularly liked about the device, what they particularly disliked, experiences with CGM alarms, challenges using the device and overall impressions. The

main benefit reported was visibility of trends and data ( $n=33$ ) with key dislike reported as technical difficulties such as alarms, connectivity and frequency of charging ( $n=23$ ). Specifically relating to alarms, there were mixed responses with 56% ( $n=28$ ) of participants reporting positive experience, however 20% ( $n=10$ ) preferred the ability to customize the alarms with 22% ( $n=11$ ) finding them too sensitive or too quiet at night. The most common occasions when participants chose not to wear the transmitter were when bathing/showering/swimming (98%,  $n=49$ ) followed by recharging (20%,  $n=10$ ). Participants were informed that the transmitter was not water tight. Furthermore, it had to be charged once daily, which could be done within 15 minutes, e.g. during bathing. Overall, the majority of participants were impressed with the system stating ease of use of making life easier ( $n=41$ ).

### **Discussion:**

Here we report that fifty-one participants who took part in the PRECISE study across the UK and Germany reported positive psychosocial outcomes while using an implantable continuous glucose monitor.

Most studies show that users receive verifiable benefit when they use CGM intensively, i.e. every day [2,6]. In practice, however up to 40% of those who use sensors discontinue use over the course of a year [9]. Even in clinical studies, sensor usage has often been below 60% in some groups [2]. There are a number of reasons for this: the cost of sensors is unaffordable for many; inaccurate measurement and interpretation of glucose information occurs; alarm fatigue; pain, irritation at the site of the sensor,[9] negative reactions from the social environment e.g. needing to justify why a technical device is being constantly worn or to explain an alarm; the overload of data and feelings of being overwhelmed by information. An implantable sensor may address some of these issues. Participants specifically cite the longevity of the device as a benefit, removing the need for frequent sensor replacements. The low visibility of the sensor device removes the visible appearance of the technology and the use of a mobile device is commonplace so avoids drawing attention to a piece of 'medical' equipment lowering the visibility of disease state.

Often, participants feel frustrated that their expectations of CGM technology are not met. Exploring expectations prior to use and revisiting these periodically may help to address this. Helping people to learn how to process the additional data provided by CGM and managing expectations around the amount of time and effort required to master the system to best meet individual needs is important to support optimal use. Furthermore, user friendliness of CGM devices has been reported as an area requiring improvement [10].

Patient reported outcome data reported here is comparable for CGM users and non-CGM users with T1D in the literature [10]; something that is reinforced in the current study with no deterioration associated with implantable CGM use. Interestingly, significantly greater benefit for convenience, acceptability of BG monitoring requirements, BG control efficacy, diabetes worries and interpersonal hassles associated with CGM and CSII use is reported [9], however participants were naïve to pump therapy as well as CGM and it is not possible to separate the impact in terms of device. All of the benefits are commonly reported as associated with insulin pump therapy, so it could be argued that the benefit in insulin therapy overshadowed CGM impact on these psychosocial outcomes.

Engagement with CGM usage is positively associated with improvements in glycemic control [10] and results from the current study show that the majority participants were routinely checking the screen to see their BG values frequently (table 1) during the trial. The ability to easily see the number and trend direction of BG travel has been widely positively reported as reassuring in closed loop research [5] and this was cited by 66% of participants as a particular benefit in the current study. The reduced burden of technology in terms of ease of use, ease to learn, ability to wear in everyday settings, convenience and comfort reported by participants addresses the needs of people with diabetes reported in the literature [11].

Strengths of the study include rigorous psychosocial assessment alongside medical outcomes in the main PRECISE trial including both quantitative and free text response options to explore potential facilitators and barriers to



sustained use of the device. Limitations of the current study include the relatively small sample size ( $n=51$ ) however this is a pilot study and further research is ongoing. Further, the lack of baseline psychosocial data makes it difficult to draw definite conclusions, however the consistency across three and six-month follow-up reflects durable impact on such factors important to quality of life of participants.

In conclusion, an implantable CGM sensor was acceptable to participants and use of the system was associated with minimized burden of diabetes. Psychosocial functioning and factors important to quality of life were reported as positively associated with the device by users.

**Acknowledgments:**

We would like to thank all of our participants from across Europe who took part in this study. We are very grateful for their time and their candid review of their experiences. We further acknowledge and thank the study personnel for their help in the successful execution of the study.

**Author Disclosure Statement**

KB has received speaker honoraria from Roche Diabetes Care, Johnson & Johnson, serving on advisory panels for Roche Diabetes Care and Animas. J.K. received research support from Senseonics Inc. and Dexcom. T.F. received research support and is a consultant/advisor/speaker for AstraZeneca, Eli Lilly and Company, Bristol-Myers Squibb, Sanofi, Boehringer Ingelheim, Novartis, Novo Nordisk, and Berlin-Chemie. J.H.D. received research support and is a consultant/advisor/speaker for Senseonics Inc., Dexcom, Johnson & Johnson (Animas, LifeScan), and Roche Diagnostics. PC has received research support and is a consultant/advisor/speaker for Medtronic, Roche, Johnson and Johnson, Novo Nordisk, Lilly and Abbott. No other potential conflicts of interest relevant to this article were reported.

## References

1. Riveline JP. Is continuous glucose monitoring (CGM) for everyone? To whom should CGM be prescribed and how? *Diabetes and Metabolism* 2011;37:80–84
2. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: Evidence from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring (JDRF-CGM) trial. *Diabetes Care* 2009;33:17–22
3. Little SA, Leelarathna L, Walkinshaw E, Horng KT, Chapple O, Lubina-Solomon AL, Chadwick TJ, Barendse S, Stocken DD, Brennard C, Marshall SM, Wood R, Speight J, Kerr D, Flanagan D, Heller SR, Evans ML and Shaw JAM. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multi-center 2x2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPASS). *Diabetes Care* 2014 Aug; 37(8): 2114-2122
4. Ritholz MD, Atakov-Castillo A, Beste M et al. Psychosocial factors associated with use of continuous glucose monitoring. *Diabetic Medicine* 2010;27:1060–1065
5. Barnard KD, Wysocki T, Allen J, Elleri D, Thabit H, Leelarathna L, Gulati A, Nodale M, Dunger D, Tinati T and Hovorka R. Closing the Loop Overnight at Home Setting: Psychosocial Impact for Adolescents with Type 1 Diabetes and their Parents. *BMJ Open Diabetes Research and Care*, March 2014
6. Kropff J, Choudhary P, Neupane S, Barnard KD, Bain SC, Kapitza C, Forst T, Link M, Dehennis A and DeVries JH. Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day Prospective, Multicenter, Pivotal Trial. *Diabetes Care* 2017 Jan; 40(1): 63-68
7. Fisher L, Glasgow RE, Mullan JT, Skaff MM and WH Polonsky. Development of a Brief Diabetes Distress Screening Instrument. *Ann Fam Med* 2008 May, 6(3): 246-252
8. Polonsky WH, Fisher L, Hessler D and Edelman SV. Development of a New Measure for Assessing Glucose Monitoring Device-Related Treatment Satisfaction and Quality of Life. *Diabetes Technol Ther.* 2015;17(9):657-663.
9. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. *BMJ* 2011;343:1-14
10. Barnard KD, N, Heinemann L. Heinemann Patient-Reported Outcomes and Continuous Glucose Monitoring: Can We Do Better With Artificial Pancreas Devices? *Diabetes care* 38(5):E70 May 2015 DOI: 10.2337/dc14-3044
11. Wong, J.C., et al., *Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry.* *Diabetes Care*, 2014. **37**(10): p. 2702-9.

Table One: Frequency of BG 'Checking' on iPod

Frequency	Therapy		CGM Use	
	CSII (n=25)	MDI (n=25)	1 <sup>st</sup> (28)	Repeat (n=22)
Every Hour or >	18	18	21	15
every 2 hours	4	5	5	4
Approx. 6 times daily	3	2	2	3

CSII – Insulin Pump User, MDI: Multiple daily injections

**Table Two: CGM Impact Scale at Three Months Follow-up**

Item	Mean Response (SD)				
	All Users	Therapy		CGM Use	
		CSII (n= 25)	MDI (n= 25)	1st (n=28)	Repeat (n=22)
Do you now feel more confident or less confident that you can control your diabetes?	1.51 (0.74)	1.56 (0.77)	1.36 (0.64)	1.39 (0.69)	1.61 (0.78)
Do you now feel more or less in control or less in control of your life and your diabetes?	1.86 (0.87)	2.04 (0.98)	1.56 (0.65)	1.79 (0.96)	1.87 (0.76)
Do you now feel more hopeful or less hopeful that you can avoid long-term complications?	1.87 (0.76)	2.12 (0.73)	1.56 (0.71)	1.75 (0.75)	1.96 (0.77)
Do you now feel more motivated or less motivated to keep up with your diabetes management?	1.80 (0.82)	1.84 (0.75)	1.72 (0.89)	1.79 (0.83)	1.78 (0.80)
Is it now harder or is it easier to adjust your insulin doses correctly?	1.96 (0.82)	1.88 (0.78)	1.92 (0.86)	1.89 (0.83)	1.96 (0.82)
Have your blood glucoses become more or become less of a "roller coaster"?	2.16 (0.85)	2.36 (0.81)	1.92 (0.81)	2.14 (0.71)	2.17 (0.98)
Has your A1C improved or has it worsened?	2.25 (0.75)	2.42 (0.58)	2.00 (0.86)	2.13 (0.80)	2.38 (0.67)
Do you now feel more free or less free to do the things in your life you really want to do?	2.24 (0.92)	2.48 (0.77)	1.92 (1.00)	2.14 (0.97)	2.30 (0.88)
Do you now feel more safe or less safe when exercising?	2.04 (0.91)	2.04 (0.79)	2.00 (1.04)	2.04 (1.00)	2.04 (0.82)
Do you now feel more safe or less safe about sleeping?	1.84 (0.85)	1.96 (0.84)	1.64 (0.86)	1.68 (0.86)	1.96 (0.82)
Do you now feel more fearful or less fearful about hypoglycemia?	2.08 (0.98)	2.12 (0.97)	1.92 (1.00)	2.00 (1.09)	2.09 (0.85)
Do you now feel more confident or less confident that you can avoid serious hypoglycemia?	1.73 (0.84)	1.68 (0.80)	1.68 (0.85)	1.57 (0.74)	1.87 (0.92)
Do you now feel more safe or less safe while driving?	2.08 (0.93)	2.04 (0.93)	2.04 (0.93)	1.93 (0.94)	2.22 (0.90)
Are your relationships with your family and friends now better or worse?	2.78 (0.59)	2.92 (0.40)	2.64 (0.70)	2.79 (0.57)	2.78 (0.60)
Is your partner now worrying less or worrying more about sleeping at night?	2.33 (0.85)	2.52 (0.77)	2.12 (0.88)	2.32 (0.86)	2.35 (0.83)
Are your friends and family now bothering you less or bothering you more about your diabetes?	2.53 (0.77)	2.72 (0.61)	2.36 (0.86)	2.61 (0.74)	2.48 (0.79)

Scale: 1=much better; 2=slightly better; 3=neutral; 4=slightly worse; 5=much worse

**Table Three: Diabetes Distress Scale – All Items at Three Month Follow-up**

Item	Mean Response (SD)				
	All Users	Therapy		CGM Use	
		CSII (n=25)	MDI (n=25)	1 <sup>st</sup> (n=28)	Repeat (n=22)
Feeling overwhelmed by the demands of living with diabetes.	1.88 (0.85)	1.96 (0.84)	1.76 (0.83)	1.75 (0.70)	2.04 (0.98)
Feeling that I am often failing with my diabetes routine.	2.00 (1.11)	2.2 (1.15)	1.68 (0.80)	1.61 (0.69)	2.48 (1.31)
Feeling that diabetes is taking up too much of my mental and physical energy every day.	1.54 (0.71)	1.56 (0.65)	1.52 (0.77)	1.39 (0.63)	1.78 (0.80)
Feeling that my doctor doesn't know enough about diabetes and diabetes care.	1.20 (0.57)	1.12 (0.33)	1.36 (0.81)	1.32 (0.72)	1.13 (0.46)
Feeling angry, scared, and/or depressed when I think about living with diabetes.	1.46 (0.68)	1.48 (0.65)	1.44 (0.71)	1.39 (0.57)	1.57 (0.79)
Feeling that my doctor doesn't give me clear enough directions on how to manage my diabetes.	1.20 (0.49)	1.2 (0.41)	1.20 (0.58)	1.14 (0.52)	1.26 (0.45)
Feeling that I am not testing my blood sugars frequently enough.	1.58 (0.99)	1.8 (1.26)	1.36 (0.57)	1.36 (0.56)	1.83 (1.30)
Feeling that I am often failing with my diabetes routine.	1.96 (1.01)	2.12 (1.09)	1.68 (0.63)	1.64 (0.68)	2.35 (1.19)
Feeling that friends or family are not supportive enough of self-care efforts (e.g. planning activities that conflict with my schedule, encouraging me to eat the "wrong" foods).	1.42 (0.76)	1.64 (0.95)	1.20 (0.41)	1.32(0.55)	1.52 (0.95)
Feeling that diabetes controls my life.	1.94 (1.04)	1.84 (0.75)	1.92 (1.12)	1.79 (0.88)	2.13 (1.18)
Feeling that my doctor doesn't take my concerns seriously enough.	1.14 (0.35)	1.17 (0.38)	1.12 (0.33)	1.11 (0.32)	1.17 (0.39)
Not feeling confident in my day-to-day ability to manage diabetes.	1.43 (0.71)	1.38 (0.49)	1.40 (0.71)	1.22 (0.42)	1.70 (0.88)
Feeling that I will end up with serious long-term complications, no matter what I do.	2.24 (1.30)	2.54 (1.53)	1.96 (0.98)	2.00 (1.21)	2.52 (1.34)
Feeling that I am not sticking closely enough to a good meal plan.	2.12 (1.25)	2.25 (1.39)	1.92 (0.95)	1.85 (0.91)	2.48 (1.50)
Feeling that friends or family don't appreciate how difficult living with diabetes can be.	2.02 (1.18)	2.25 (1.33)	1.76 (0.93)	1.67 (0.88)	2.48 (1.34)
Feeling overwhelmed by the demands of living with diabetes.	1.57 (0.79)	1.63 (0.65)	1.44 (0.77)	1.37 (0.63)	1.83 (0.89)
Feeling that I don't have a doctor who I can see regularly enough about my diabetes.	1.14 (0.46)	1.08 (0.28)	1.2 (0.58)	1.19 (0.56)	1.09 (0.29)
Not feeling motivated to keep up my diabetes self management.	1.49 (0.77)	1.58 (0.65)	1.36 (0.86)	1.22 (0.42)	1.78 (0.95)
Feeling that friends or family don't give me the emotional support that I would like.	1.43 (0.84)	1.58 (1.06)	1.32 (0.56)	1.19 (0.40)	1.74 (1.10)

